ORIC Pharmaceuticals (NASDAQ:ORIC) Receives Buy Rating from Guggenheim
Guggenheim restated their buy rating on shares of ORIC Pharmaceuticals (NASDAQ:ORIC – Free Report) in a research note issued to investors on Wednesday,Benzinga reports. Other research analysts have also issued research reports about the company. JPMorgan Chase & Co. lifted their price target on ORIC Pharmaceuticals from $19.00 to $21.00 and gave the stock an […]
Guggenheim restated their buy rating on shares of ORIC Pharmaceuticals (NASDAQ:ORIC – Free Report) in a research note issued to investors on Wednesday,Benzinga reports. Other research analysts have also issued research reports about the company. JPMorgan Chase & Co. lifted their price target on ORIC Pharmaceuticals from $19.00 to $21.00 and gave the stock an […]
